Locust Walk Insights CATEGORIES Asian Capabilities Capital Raising Commercial Assessment Locust Walk Institute Market Trends Multitrack Process Negotiation Partnering Quarterly Reports ARCHIVE 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 LOCUST WALK INSIGHTS 2025 Q3 Report: Global Trends in Biopharma Transactions October 8, 2025 2025 Q2 Report: Global Trends in Biopharma Transactions July 10, 2025 2025 Q1 Report: Global Trends in Biopharma Transactions April 11, 2025 China Supermarket: Is the Value for Money Due to Global Development Expertise or Superior Negotiation? March 17, 2025 2024 Year-In-Review Report: Global Trends in Biopharma Transactions January 11, 2025 Overview of AI in Biotech April 3, 2024 2023 Year-In-Review Report: Global Trends in Biopharma Transactions January 6, 2024 Deal Makers of Japan, Volume 3 May 31, 2023 RNA Therapeutics Landscape Overview February 22, 2023 2022 Year In Review Report: Global Trends in Biopharma Transactions January 8, 2023 Breakthrough Innovation Reports: Oncology IPS-Effector Cell Therapies April 5, 2022 Breakthrough Innovation Reports: Regenerative Medicine iPS-Cell Therapy Investment Insights and Emerging Players March 31, 2022 2021 Year End Report January 10, 2022 Bought Not Sold October 13, 2021 iPSC Market Overview October 4, 2021 Crossover Evolution: The Evolving Role of the Crossover Financing Round April 28, 2021 Locust Walk 2020 Year End Report January 28, 2021 Doubling Down: The Power of Asset Diversification in a Time of Robust Access to Capital December 14, 2020 Biopharma’s COVID Capital Comeback – A Whitepaper September 14, 2020 A Brave New World: Japan Pharma and COVID-19 June 23, 2020 Deal Makers of Japan, Volume 2 June 15, 2020 Strategic Implications of COVID-19 on Biopharma March 20, 2020 Deal Theory: a Biopharma Deal Maker’s Approach to Maximizing Strategic Partnerships March 19, 2020 Deal Makers of Japan, Volume 1 March 3, 2020 2019 Year End Review Biopharma Report January 11, 2020 2019 Medtech Year End Review Report January 11, 2020 Whitepaper Download: Inside Out September 16, 2019 My (National Lampoon’s) European Vacation August 21, 2019 Financing overhang or hangover: The impact on partnerships for public biotech companies July 30, 2019 Global Business Reports Interview with Geoff Meyerson, CEO & Co-Founder of Locust Walk May 6, 2019 Greed is Bad: Why Defendable Commercial Assessments are Better Than Pie in the Sky April 30, 2019 The Art of the Multi-Track Deal Whitepaper April 8, 2019 Make No Bones About It – AAOS 2019 Was All About M&A and Promising New Technology March 20, 2019 The Asia Factor Whitepaper March 11, 2019 Trends in Venture Deal Term Sheets: Favorable Climate for Founders February 22, 2019 Indication Selection for a Platform Company: The Faustian Dilemma December 13, 2017 Explain Yourself! Avoiding Common Communications Pitfalls During Term Sheet Negotiations December 6, 2017 Japan & China: So close yet so different November 30, 2017 Late-Stage Biopharma IPOs and the Commercialization Partnership – Predictor of Success? November 21, 2017 Maximizing Your JP Morgan Healthcare Conference November 15, 2017 Finding the invisible, how to meet Family Offices November 2, 2017 Navigating the MedTech Fundraising Environment October 25, 2017 Demystifying the Venture Capital Term Sheet October 11, 2017 When to use a structured deal process? October 5, 2017 Key trends impacting Japan partnering September 13, 2017 Getting Taken to School: Key Considerations and Differentiators of why “Academic” Transactions Have Typically Lower Deal Values than Industry Transactions August 29, 2017 Maximizing the Likelihood of Closing a Deal This Year August 15, 2017 Why is Family Office money so hard to find for life science companies? August 8, 2017 Ask the Experts: The Importance of Including Subject Matter Experts in Deal Discussions August 2, 2017 Helping to Ensure Success After the Deal June 21, 2017 The Best Buyers Are The Best Sellers June 6, 2017 Maintaining Deal Momentum in the Summertime May 31, 2017 Looking at Deal Value Beyond the Headlines May 24, 2017 Companies are bought, because they are sold May 17, 2017 Finding the Right Partner May 3, 2017 Looking East – Geographic Considerations when Partnering Regionally in Asia April 26, 2017 It’s Not You, It’s US: The Value of Keeping US Rights in Biopharma Partnering April 25, 2017 Executing a successful buy-side transaction for commercial stage companies April 12, 2017 Deal Strategy and Objectives March 29, 2017 Life is Long, Don’t Give Up March 23, 2017 The Potential Impact of FDA Leadership Changes on Drug Partnership March 15, 2017 What happened to the value of priority review vouchers (PRV)? March 2, 2017 Immunomedics and venBio: Activist Investors in Biotech February 22, 2017 The Uneven Pendulum: Measuring Upside and Downside in Biopharma Stock Performance February 15, 2017 How to Get Deal Experience Without Having Deal Experience January 25, 2017 Japan Licensing Deals: A look back at 2016, and what to expect in 2017 January 18, 2017 Business Development Implications of the 21st Century Cures Act December 14, 2016 The Case for Europe. December 7, 2016 Immuno-Oncology Deals: Why Are They So Hot? December 1, 2016 A bird in the hand is worth two in the bush. November 22, 2016 New Horizons of the Regenerative Medicine Space in Japan November 15, 2016 Implications of the US election on the Life Science Industry November 9, 2016 Maximizing Buy Side Success as a Smaller Company November 2, 2016 Creating an Event Horizon for Your Deal October 28, 2016 Why medical device companies can benefit from a commercial assessment early on? October 20, 2016 Business Development Confidential: Using CDAs and Data Rooms to Structure a Transaction Process October 14, 2016 The Art of the Life Sciences Deal October 6, 2016 How to Survive the Biotech Roller Coaster Ride September 28, 2016 Stock vs. Asset Purchase Agreements: One Word Can Make a World of Difference September 21, 2016 The Improving Japanese Pharmaceutical Regulatory Environment September 14, 2016 Geoff Meyerson – The Business of Convergence by Stacey Alcorn September 8, 2016 Best Practices to Effectively Manage Due Diligence September 8, 2016 Best Practices to Prepare for a Sell-Side Process September 1, 2016 Three Main Factors to Focus on When Valuing an Asset August 25, 2016 Negotiation Tactics: How to Maximize Deal Value August 17, 2016 Five Tips to Successfully Raise Family Office Capital August 2, 2016 Q2 2016 Trends in Biotech Finance August 1, 2016 How to Approach Regional Partnering Deals in Japan and Asia July 25, 2016 How to Approach Regional Partnering Deals in Japan and Asia July 25, 2016 The Value of A Commercial Assessment in Supporting a Transaction July 14, 2016 The Value of A Commercial Assessment in Supporting a Transaction July 14, 2016 Partnering Your Drug – To Provide Deal Terms Guidance or Not July 7, 2016 Brexit’s Impact on Development Stage Biopharma June 29, 2016 Locust Walk’s Japanese Presence Expedites Licensing Agreement for Client Medgenics June 21, 2016 Recap of Spring 2016 Locust Walk Institute: Financing your biotech from idea to IPO May 11, 2016 Advantages of Running a Multitrack Process April 14, 2016 How to Finance a Commercial Product Acquisition April 12, 2016 5 Mistakes an Entrepreneur Makes When Raising Capital April 5, 2016 Eat Or Be Eaten: Controlling Your Fate In The Specialty Pharma MA Feeding Frenzy July 23, 2015 Not-for-profits seeking stronger partnerships in return for early dollars May 12, 2015
